Corcept Therapeutics Inc (CORT)
27.95
+0.29
(+1.05%)
USD |
NASDAQ |
May 15, 15:29
Corcept Therapeutics Net Income (Quarterly): 27.76M for March 31, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 27.76M |
December 31, 2023 | 31.36M |
September 30, 2023 | 31.38M |
June 30, 2023 | 27.53M |
March 31, 2023 | 15.88M |
December 31, 2022 | 16.60M |
September 30, 2022 | 34.61M |
June 30, 2022 | 27.41M |
March 31, 2022 | 22.80M |
December 31, 2021 | 32.05M |
September 30, 2021 | 30.47M |
June 30, 2021 | 26.52M |
March 31, 2021 | 23.46M |
December 31, 2020 | 25.99M |
September 30, 2020 | 21.62M |
June 30, 2020 | 28.33M |
March 31, 2020 | 30.06M |
December 31, 2019 | 29.38M |
September 30, 2019 | 26.34M |
June 30, 2019 | 20.19M |
March 31, 2019 | 18.27M |
December 31, 2018 | 22.01M |
September 30, 2018 | 17.75M |
June 30, 2018 | 18.20M |
March 31, 2018 | 17.46M |
Date | Value |
---|---|
December 31, 2017 | 98.33M |
September 30, 2017 | 13.76M |
June 30, 2017 | 12.65M |
March 31, 2017 | 4.388M |
December 31, 2016 | 4.597M |
September 30, 2016 | 2.585M |
June 30, 2016 | 0.977M |
March 31, 2016 | -0.019M |
December 31, 2015 | 0.959M |
September 30, 2015 | -0.601M |
June 30, 2015 | -1.936M |
March 31, 2015 | -4.83M |
December 31, 2014 | -3.895M |
September 30, 2014 | -6.006M |
June 30, 2014 | -7.552M |
March 31, 2014 | -13.93M |
December 31, 2013 | -11.12M |
September 30, 2013 | -10.91M |
June 30, 2013 | -11.90M |
March 31, 2013 | -12.08M |
December 31, 2012 | -11.12M |
September 30, 2012 | -8.293M |
June 30, 2012 | -7.597M |
March 31, 2012 | -11.03M |
December 31, 2011 | -9.936M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
15.88M
Minimum
Mar 2023
34.61M
Maximum
Sep 2022
26.49M
Average
27.47M
Median
Net Income (Quarterly) Benchmarks
Ultragenyx Pharmaceutical Inc | -170.68M |
Alnylam Pharmaceuticals Inc | -65.94M |
Catalyst Pharmaceuticals Inc | 23.28M |
United Therapeutics Corp | 306.60M |
XOMA Corp | -8.595M |
Net Income (Quarterly) Related Metrics
Revenue (Quarterly) | 146.81M |
Total Expenses (Quarterly) | 117.31M |
EPS Diluted (Quarterly) | 0.25 |
Enterprise Value | 2.469B |
Gross Profit Margin (Quarterly) | 98.27% |
Profit Margin (Quarterly) | 18.91% |
Earnings Yield | 3.79% |
Operating Earnings Yield | 3.95% |
Normalized Earnings Yield | 3.792 |